Health Canada and Research Peptides: What the 2024 to 2026 Enforcement Record Actually Says

Between June 2024 and April 2026, Health Canada published a run of public advisories about research peptides. Two of them named specific Canadian sellers and listed, product by product, exactly what had been seized. One of them stated in a single sentence what the department thinks of "research use only" labelling. Almost nobody selling peptides in this country has quoted that sentence back to you.

We are a Canadian supplier of research-grade peptides, so we have an obvious interest in how this subject gets written about. This article is our attempt to write the version we could not find: the actual enforcement record, read from the primary advisories rather than summarised from other people's summaries, with the parts that are inconvenient for suppliers left in.

Nothing here is legal advice, and nothing here is a claim that any product sold for laboratory use is authorised by Health Canada. No research-use-only peptide is. That is the point of the article, and understanding why is the difference between buying carefully and buying blind.

The record, in one table

Everything in this table comes from the primary document, not from coverage of it. Dates are the publication dates carried by the advisories themselves.

Two things stand out when the five documents are read in sequence.

The first is that the enforcement is not aimed at chemistry. Nothing in any of the advisories argues that a particular peptide sequence is inherently dangerous or inherently prohibited. The objection is uniform and it is regulatory: these products have not been assessed for safety, efficacy and quality, which is the standing formula Health Canada uses for anything without a market authorisation.

The second is that the two Canadian actions look similar for a reason. Compare the catalogues.

Two separately named sellers, one in the enforcement record four months after the other, offering close to the same set of compounds. That convergence is not a coincidence and it is not evidence of a shared conspiracy either. It is what a market looks like when a small number of upstream synthesis houses supply nearly everyone, and the differentiation happens at the label rather than at the molecule.

Which is precisely why the documentation matters more here than the branding does. If the material behind two storefronts can be the same, the only thing separating them is what each one can prove about the specific lot it shipped you.

The legal test is representation, not molecule

This is the part most buyer guides get wrong, and getting it wrong makes everything downstream incoherent.

Section 2 of the Food and Drugs Act defines a drug as:

any substance or mixture of substances manufactured, sold or represented for use in (a) the diagnosis, treatment, mitigation or prevention of a disease, disorder or abnormal physical state, or its symptoms, in human beings or animals, (b) restoring, correcting or modifying organic functions in human beings or animals, or (c) disinfection in premises in which food is manufactured, prepared or kept.

Read the verbs: manufactured, sold or represented. The definition is not a list of molecules. It is a test applied to conduct. The same white powder can sit outside the definition as a laboratory reagent and inside it the moment somebody sells it, or represents it, for modifying organic functions in a person.

That is why the advisories read the way they do. Health Canada is not saying that BPC-157 is a controlled substance. It is saying that a seller who offers an injectable BPC-157 product to the public has sold a drug, and that drug has no market authorisation.

Three consequences follow, and all three are practical rather than theoretical.

"Research use only" is a statement about representation, not a shield. Health Canada's 9 April 2026 advisory is unambiguous that the phrase does not create an exemption. But it does not follow that the phrase is meaningless. It goes to the same element the statute turns on. A seller whose entire surface, product pages, images, support replies and social posts, is consistent with laboratory use is in a materially different position from one who prints the disclaimer on the vial and then publishes personal-use guidance next to it. The disclaimer is not a shield. The behaviour it describes is what matters, and the disclaimer without the behaviour is worth nothing at all.

Schedule F no longer exists. A striking number of Canadian peptide guides still explain the market in terms of Schedule F to the Food and Drug Regulations. Schedule F was repealed by SOR/2013-122, published in the Canada Gazette on 19 June 2013, and replaced by the Prescription Drug List, an administrative list maintained by the Minister of Health and updated on a rolling basis. Every ingredient that was on Schedule F was carried over. The list is real and the concept survives, but the instrument changed thirteen years ago. When a guide cites a repealed schedule as current law, it is telling you that nobody checked.

Authorised products carry a DIN. Health Canada's own instruction to consumers, repeated across the advisories, is to look for the eight-digit Drug Identification Number on the label and to search the Drug Product Database. Semaglutide and tirzepatide are authorised in Canada, as prescription medicines, dispensed by licensed pharmacies, with DINs. A research-grade vial of the same sequence is not that product, does not have a DIN, and never will. Anyone who blurs those two things is either confused or hoping you are.

What the advisories say about the supply, not just the law

Regulatory framing is only half of what these documents contain. The other half is a quiet description of the material itself.

Health Canada's stated risk list for unauthorised drugs is worth reading closely, because each item is a failure mode with an analytical test attached:

The published literature says the same thing from the other direction. Krug and colleagues, writing in Growth Hormone and IGF Research in 2018, characterised products bought from the growth-promoting black market by high resolution mass spectrometry. What they found was not simply weak material. They found a modified growth hormone carrying 192 amino acids with an additional alanine residue, and three growth hormone releasing peptide analogues that were not the compounds on the label: Gly-GHRP-6, Gly-GHRP-2 and Gly-Ipamorelin.

That result is the single most useful thing a buyer can know about identity testing. An analogue differing by one residue is a different molecule with a different mass, and high resolution mass spectrometry resolves it immediately. A cheap identity check that reports only "conforms" or a retention time will not. The failure mode is not "we sold you a weaker version". It is "we sold you a compound with a name nobody has published a safety profile for", and the only instrument that reliably distinguishes the two is the one many certificates quietly omit.

The WHO alert adds the final piece. The three falsified semaglutide batches it identified were detected inside the regulated supply chain, in pharmacy distribution, in three countries. One of the three batch numbers, MP5E511, was a genuine manufacturer batch number applied to falsified product. If a batch number printed on a licensed pharmaceutical carton can be a copy of a real one, then a batch number printed on a research vial proves nothing on its own either. It only becomes evidence when it is tied to a specific analytical document that a specific laboratory issued for that specific lot.

Purity is not one number

Every peptide storefront in Canada advertises a purity figure. Almost none of them explain what the figure is measuring, and the gap between the two most common interpretations is large enough to change what you actually received.

HPLC area percent is the number on nearly every certificate. The sample is separated by reverse-phase chromatography, the detector response is integrated, and the target peak's area is expressed as a percentage of the total integrated area. It answers one question well: of the material that eluted and absorbed at the detection wavelength, what fraction was the target?

Net peptide content answers a different question: of the total mass of powder in the vial, what fraction is peptide at all? The remainder is not necessarily contamination in any sinister sense. Synthetic peptides purified by preparative HPLC in trifluoroacetic acid are isolated as TFA salts, and the counter ion is real mass. Lyophilised powder also picks up water. Between counter ion and residual moisture, a peptide can be 99 percent pure by HPLC area and still be well under 90 percent peptide by mass.

Both numbers are honest. They are answers to different questions, and a vial can be excellent on one and unremarkable on the other. USP General Chapter 1503, Quality Attributes of Synthetic Peptide Drug Substances, published in August 2021, is the reference that sets out the full attribute list rather than the single headline figure:

The right expectation for research-grade material is not that every row is populated. Most research certificates carry identity and related substances and stop there, and for a great deal of in-vitro work that is a defensible package. The right expectation is that the vendor knows which rows are missing and will say so plainly when asked. A supplier who responds to "do you have net peptide content for this lot?" with a straight "no, we run identity and purity only" has told you something reassuring. A supplier who responds by restating the HPLC number more loudly has told you something else.

The lot-match chain

This is the cheapest check in the entire process and it catches the most common failure. Four artefacts have to carry the same identifier.

A certificate that fails link 3 is not a weak certificate. It is a document about a different batch, and its purity figure carries no information about the powder you are holding. The check takes fifteen seconds and it is the one people skip.

One more point on link 2. Note what happened at phxlab.net: at Health Canada's request the company stopped selling and the website came down. Every certificate hosted only on that site went down with it. If a supplier's documentation lives exclusively behind their own login, your evidence has the same lifespan as their domain registration. Download the certificate for every lot you buy, on the day you buy it, and keep it locally.

Red flags, scored

Every buyer guide has a red flag list. Lists are hard to act on because they do not tell you how much any single item should move you. Here is the same idea as a rubric. Score a supplier before you order and use the total, not any individual line.

How to read the total. 0 to 4: normal for a small vendor, proceed with a single-vial test order. 5 to 9: get specific answers in writing before ordering. 10 or more, or any single 8-point item: do not order, regardless of how good the rest of the page looks.

The scoring matters because the failures cluster. A vendor with no laboratory named, no lot on the certificate and a price below cost is not three small problems. It is one problem showing through in three places.

The cross-border question

Domestic fulfilment is presented as a convenience by most Canadian vendors. The more accurate framing is legal, and it is set out in CBSA Memorandum D19-9-1, which governs how the Canada Border Services Agency administers Health Canada's legislation at the border.

The personal-importation allowances are narrower than the internet believes:

• Personal importation of drugs is permitted for visitors to Canada, practitioners, and registered pharmacists, for their own personal use, and is limited to a 90-day supply.
• Shipments exceeding a 90-day supply are not permitted, and repeat shipments of the same product within 90 days whose combined quantity exceeds that limit are likewise prohibited.
• For Canadian residents, importing prescription drugs by mail or courier for personal use is generally prohibited. The discretionary exception contemplated is a resident returning from abroad carrying a course of treatment with them, which is not a courier parcel.

Two things follow. First, a Canadian resident ordering from an offshore vendor should not assume the parcel is merely at risk of delay. Second, and more usefully: a package that is examined and held sits in a facility with no temperature control for as long as the examination takes. Even a parcel that is eventually released has spent that time outside any storage condition its certificate assumed. The document still says what the lot was at release. It no longer describes what arrived.

This is the substantive argument for domestic fulfilment, and it is stronger than the marketing version. It is not that a border is inconvenient. It is that a border introduces an uncontrolled and undocumented gap in the chain of custody between the analysis and your bench.

Receipt, storage, and the things that actually degrade

Lyophilised peptide is stable. Lyophilised peptide is not indifferent. The distinction is worth holding precisely, because vendors on both sides overstate their case.

• Lyophilised powder tolerates transit. Short excursions to ambient temperature during shipping are ordinarily fine for most sequences, which is why the entire industry ships this way. A supplier who tells you their powder will be ruined by two warm days is selling anxiety.
• Moisture is the real enemy. Water uptake is what converts a stable powder into a slowly hydrolysing one. This is why the vial is under vacuum, why the stopper matters more than the ice pack, and why a vial that arrives with a lifted or unseated stopper is a problem even when it is cold.
• Reconstituted material is a different substance in stability terms. Once in solution the clock runs much faster, and stability becomes sequence-specific. Treat solution stability as a property of the individual compound rather than a general rule.
• Inspect before you open. Outer seal intact, thermal protection appropriate to the season, vial visibly whole, cake present and not collapsed to a film or a ring of residue, stopper fully seated. Photograph anything wrong before touching it. Reconstituting a suspect vial destroys the evidence and ends the conversation with the vendor.

For handling detail we keep separate documents rather than repeating them here: our peptide storage guide and reconstitution guide cover the laboratory procedure, and the bacteriostatic water guide covers solvent selection.

Payment, and what recourse actually exists

The payment method chosen determines what happens when something goes wrong, and it is chosen before you know whether anything will.

For a first order with a new supplier, use the rail that preserves a dispute path even if it costs slightly more. The premium is small and the information is worth it. If a shipment does arrive compromised: photograph the outer packaging, the vial and the seal before opening anything, keep the packaging, and contact the supplier the same day with the images attached. How that conversation goes tells you more about a vendor than any page on their website.

Running the audit on ourselves

It would be strange to publish a rubric and then not apply it. Here is Volta Peptides scored against our own table, including the rows where we do not currently pass.

The empty COA library row and the identity row are the two a competitor would use against us, which is exactly why they belong in the table. The certificates exist and ship with orders. The public archive does not currently exist, and until it does, the correct thing for a careful buyer to do is ask us for the certificate for the specific lot before ordering and check that the lot number matches what arrives. That is the same instruction we would give you for any supplier, us included.

[[PRODUCT_CAROUSEL]]

What to do before your next order

1. Score the vendor against the rubric above before you look at a single price. Ten points, or any single eight-point item, ends the evaluation.
2. Request the certificate for the lot currently in stock, not a sample document. Ask three specific questions: which laboratory ran it, what the identity method was, and whether net peptide content was determined. The character of the answer is the test.
3. Check the four-link chain once the certificate is in hand, and again when the vial arrives. Lot number on the listing, on the certificate, on the label, and in your own record.
4. Order one vial. A first order is a test of a supplier's process, not an opportunity to stock a shelf.
5. Photograph the parcel on arrival before opening it, and inspect the seal, the cake and the stopper before you reconstitute anything.
6. Download and keep the certificate locally. Vendor websites come down, sometimes at a regulator's request, and they take their hosted documents with them.
7. Write it down. Lot, receipt date, condition, storage location, and the date of first reconstitution. A result you cannot trace to a vial is a result you cannot defend.

If you want the longer treatment of the purchasing side rather than the regulatory side, our complete guide to buying peptides in Canada covers grades of material, analytical interpretation and landed cost in depth, and where to buy peptides in Canada online is the compressed twenty-minute version of supplier evaluation.

Frequently Asked Questions

Are research peptides legal in Canada?

The question is not quite answerable as posed, because legality here attaches to conduct rather than to a molecule. Section 2 of the Food and Drugs Act defines a drug by what a substance is manufactured, sold or represented for use in. A peptide sold and used as a laboratory reagent is not being represented for use in modifying organic functions in a person. The same peptide sold to the public as an injectable product is, and Health Canada has repeatedly stated that such products are unauthorised and that selling unauthorised drugs is illegal in Canada. Nothing on this page is legal advice, and anyone whose situation turns on the answer should get advice from a Canadian regulatory lawyer.

Does a "research use only" label protect a seller or a buyer?

No, and Health Canada has said so in writing. Its 9 April 2026 public advisory states that products marketed as "For Research Use Only, Not for Human Consumption" continue to be identified as unauthorised, and that the labelling does not make them legal or exempt from regulatory requirements. The label is relevant because representation is the statutory test, but the label alone, unsupported by everything else a seller publishes and does, carries no weight.

What did Health Canada actually seize from Canadian peptide sellers?

In a public advisory dated 1 August 2025, Health Canada warned that unauthorised injectable peptide drugs had been seized from Canada Peptide, listing more than 40 compounds sold through the company's website. In a second advisory dated 24 December 2025 it named Rize Fitness at 188 Smithe Street in Vancouver, along with the website phxlab.net, listing more than 20 products sold under the PHX Labs name. In both cases the stated basis was the same: the products had not been assessed for safety, efficacy and quality, because they had never been authorised.

Is Schedule F still how peptides are classified in Canada?

No. Schedule F to the Food and Drug Regulations was repealed by SOR/2013-122, published in the Canada Gazette on 19 June 2013, and replaced by the Prescription Drug List. Every medicinal ingredient on the old schedule was carried onto the new list, so the substance of the classification survived, but the instrument did not. A current guide should be citing the Prescription Drug List.

What is the difference between HPLC purity and net peptide content?

HPLC area percent expresses the target peak's area as a fraction of the total integrated peak area, which tells you how much of the material that eluted was the target. Net peptide content tells you what fraction of the powder's mass is peptide at all, with the balance being counter ion, typically trifluoroacetate from preparative purification, and residual water. A lot can report 99 percent by HPLC and considerably less by mass. USP General Chapter 1503 lists both as separate quality attributes for exactly this reason.

Can I import research peptides into Canada myself?

CBSA Memorandum D19-9-1 sets out the personal-importation allowances, and they are narrow. Personal importation of drugs is permitted for visitors to Canada, practitioners and registered pharmacists for their own personal use, limited to a 90-day supply, and importing prescription drugs by mail or courier for personal use is generally prohibited for Canadian residents. Separately from the legal question, a parcel held for examination spends that time in uncontrolled storage, which breaks the chain of custody between the analysis and the material you receive.

How do I tell a real certificate of analysis from a fabricated one?

Start with the lot number, and check that it matches the vial. Then look for a named laboratory, a test date, the analytical method with its detection wavelength, and legible instrument output rather than a bare percentage. Identity should be evidenced, not asserted: a mass spectrum with an observed mass matching the theoretical mass to within a fraction of a Dalton is evidence, and the word "conforms" on its own is not. Our guide to reading a certificate of analysis works through the document field by field.

Why do two vendors selling the same compound publish the same purity figure?

Often because the material came from the same place. The overlap between the two seized Canadian catalogues is a good illustration: a small number of upstream synthesis houses supply a large share of this market, and differentiation frequently happens at the label rather than at the molecule. That is an argument for judging suppliers on lot-level documentation and operational conduct rather than on branding, since branding is the layer most easily changed.

Sources

Every claim above traces to one of these. Where a date is given in the article, it is the date carried by the document itself.

• Health Canada, public advisory, Think twice before injecting peptides bought online: unauthorized products can seriously harm you, 9 April 2026. recalls-rappels.canada.ca
• Health Canada, public advisory, Thinking about buying GLP-1 drugs like Ozempic or Mounjaro? Beware of fake or unauthorized products, 21 January 2026. recalls-rappels.canada.ca
• Health Canada, public advisory, Unauthorized health products sold online and seized at Rize Fitness may pose serious health risks, 24 December 2025. recalls-rappels.canada.ca
• Health Canada, public advisory, Unauthorized injectable peptide drugs seized and sold by Canada Peptide may pose serious health risks, 1 August 2025. recalls-rappels.canada.ca
• World Health Organization, Medical Product Alert N°2/2024: Falsified OZEMPIC (semaglutide), 19 June 2024. who.int)
• Food and Drugs Act, R.S.C. 1985, c. F-27, section 2. laws-lois.justice.gc.ca
• Regulations Amending Certain Regulations Concerning Prescription Drugs (Repeal of Schedule F to the Food and Drug Regulations), SOR/2013-122, Canada Gazette Part II, 19 June 2013. gazette.gc.ca
• Health Canada, About the Prescription Drug List. canada.ca
• Canada Border Services Agency, Memorandum D19-9-1: The Administration of Health Canada Acts and Regulations Relating to Certain Controlled, Prohibited or Regulated Goods. cbsa-asfc.gc.ca
• United States Pharmacopeia, General Chapter 〈1503〉 Quality Attributes of Synthetic Peptide Drug Substances, official 1 August 2021. doi.usp.org
• Krug O, Thomas A, Malerød-Fjeld H, Dehnes Y, Laussmann T, Feldmann I, Sickmann A, Thevis M. Analysis of new growth promoting black market products. Growth Hormone & IGF Research. 2018;41:1-6. doi:10.1016/j.ghir.2018.05.001

Volta Peptides supplies research-grade peptides for in-vitro laboratory use only. Nothing sold or described here is authorised by Health Canada, carries a Drug Identification Number, or is intended for human or veterinary use. This article is general information about a regulatory record, not legal advice, and not medical advice.